# US 2025/0082794 A1 · Antimony chelates for targeted auger therapy and imaging diagnostics

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0082794 A1
- Document ID: US20250082794A1
- Status: Published application
- Kind: A1
- Application number: 18/826,309
- Filed: 2024-09-06
- Published: 2025-03-13
- Earliest claimed: 2023-09-07
- Applicants: Wisconsin Alumni Research Foundation; UT-Battelle, LLC
- Inventors: Jonathan W. Engle; Aeli Olson; Nikki Thiele; Briana R. Schrage; Md Faizul Islam
- Web page: https://patentgrep.com/patent/US20250082794A1

## CPC

- A61K 51/0402: {carboxylic acid carriers, fatty acids (amino acids A61K51/0406)}
- A61K 51/0497: {conjugates with a carrier being an organic compounds}
- A61K 51/0478: {complexes from non-cyclic ligands, e.g. EDTA, MAG3}
- A61K 51/06: Macromolecular compounds {, carriers being organic macromolecular compounds, i.e. organic oligomeric, polymeric, dendrimeric molecules (peptides, proteins, polyamino acids A61K51/08; antibodies A61K51/10)}
- A61K 51/088: {conjugates with carriers being peptides, polyamino acids or proteins (antibodies A61K51/10)}
- A61K 51/1096: {radioimmunotoxins, i.e. conjugates being structurally as defined in A61K51/1093, and including a radioactive nucleus for use in radiotherapeutic applications}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

Antimony (Sb) chelates for use in targeted auger therapy and imaging diagnostics are provided. Also provided are methods of treating a subject in need of treatment using the antimony chelates. The chelates comprise a chelating ligand that binds an Sb radionuclide in a +5-oxidation state, such as 119Sb and 117Sb. The chelating ligand renders the Sb radionuclide stable and inert in vivo and enables the conjugation of the chelate to a biological targeting vector.

## Claims

### Claim 1

An antimony chelate comprising an antimony (Sb(V)) radionuclide bound to a chelating ligand having the chemical structure:
or a pharmaceutically acceptable salt thereof, where Ar1, Ar2, and Ar3 are independently selected from substituted or unsubstituted catechol groups and substituted or unsubstituted hydroxypyridinone (HOPO) groups.

### Claim 2 (depends on 1)

The antimony chelate of claim 1, wherein at least one of Ar1, Ar2, and Ar3 comprises a substituted or unsubstituted catechol group.

### Claim 3 (depends on 1)

The antimony chelate of claim 1, wherein Ar1, Ar2, and Ar3 each comprises a substituted or unsubstituted catechol group.

### Claim 4 (depends on 1)

The antimony chelate of claim 1, wherein at least one of Ar1, Ar2, and Ar3 comprises a substituted or unsubstituted hydroxypyridinone (HOPO) group.

### Claim 5 (depends on 1)

The antimony chelate of claim 1, wherein each of Ar1, Ar2, and Ar3 comprises a substituted or unsubstituted hydroxypyridinone (HOPO) group.

### Claim 6 (depends on 1)

The antimony chelate of claim 1, wherein at least one of Ar1, Ar2, and Ar3 is a substituted catechol group having the structure:
where R1, R2, and R3 are independently selected from H atoms, ring substituents comprising a functional group capable of forming a covalent bond to a biological targeting vector, ring substituents comprising a biological targeting vector, electron withdrawing ring substituents, electron donating ring substituents, and solubilizing ring substituents.

### Claim 7 (depends on 1)

The antimony chelate of claim 1, wherein at least one of Ar1, Ar2, and Ar3 has the structure:
or the structure
where R1, R2, and R3 are independently selected from H atoms, ring substituents comprising a functional group capable of forming a covalent bond to a biological targeting vector, ring substituents comprising a biological targeting vector, electron withdrawing ring substituents, electron donating ring substituents, and solubilizing ring substituents.

### Claim 8 (depends on 1)

The antimony chelate of claim 1, wherein at least one of Ar1, Ar2, and Ar3 is a substituted Me-3,2-HOPO group having the structure:
where R2 and R3 are independently selected from H atoms, ring substituents comprising a functional group capable of forming a covalent bond to a biological targeting vector, ring substituents comprising a biological targeting vector, electron withdrawing ring substituents, electron donating ring substituents, and solubilizing ring substituents.

### Claim 9 (depends on 1)

The antimony chelate of claim 1, wherein at least one of Ar1, Ar2, and Ar3 has a ring substituent comprising an amine group, a carboxylic acid group, an NCS group, an acyl chloride, an NCO group, an alkyne, an azide, a tetrazine, a maleimide, or an activated ester.

### Claim 10 (depends on 1)

The antimony chelate of claim 1, wherein at least one of Ar1, Ar2, and Ar3 is conjugated to a biological targeting vector.

### Claim 11 (depends on 10)

The antimony chelate of claim 10, wherein the biological targeting vector is a hormone, a signaling molecule, an antibody, a peptide, an enzyme, a nucleobase-containing moiety, or a lectin.

### Claim 12 (depends on 1)

The antimony chelate of claim 1, wherein the antimony (Sb(V)) radionuclide is 119Sb.

### Claim 13 (depends on 1)

The antimony chelate of claim 1, wherein the antimony (Sb(V)) radionuclide is 117Sb or 118mSb.

### Claim 14 (depends on 9)

The antimony chelate of claim 9, wherein the ring substituent comprises an amine group attached to Ar1, Ar2, or Ar3 via on organic linker chain comprising an ether group and the organic linker chain is covalently bonded to Ar1, Ar2, or Ar3 via an amide bond.

### Claim 15 (depends on 14)

The antimony chelate of claim 14, wherein the organic linker chain comprising an ether group comprising a polyether polyol chain.

### Claim 16 (depends on 10)

The antimony chelate of claim 10, wherein the biological targeting vector is attached to Ar1, Ar2, or Ar3 via on organic linker chain comprising an ether group, the organic linker chain is covalently bonded to Ar1, Ar2, or Ar3 via an amide bond, and the organic linker chain is bonded to the biological targeting vector via an amide bond.

### Claim 17 (depends on 16)

The antimony chelate of claim 16, wherein the biological targeting vector is Vipivotide tetraxetan or 2-[3-(1,3-dicarboxypropyl)ureido]pentanedioic acid.

### Claim 18 (depends on 10)

The antimony chelate of claim 10, wherein the biological targeting vector is attached to Ar1, Ar2, or Ar3 via on organic linker chain comprising an ether group, the organic linker chain is covalently bonded to Ar1, Ar2, or Ar3 via an amide bond, and the organic linker chain is bonded to the biological targeting vector via a thiourea bond.

### Claim 19 (depends on 18)

The antimony chelate of claim 18, wherein the biological targeting vector is Vipivotide tetraxetan or 2-[3-(1,3-dicarboxypropyl)ureido]pentanedioic acid.

### Claim 20

A method of treating a subject in need of treatment, the method comprising administering a therapeutically effective amount of the antimony chelate comprising an antimony (Sb(V)) radionuclide bound to a chelating ligand having the chemical structure:
or a pharmaceutically acceptable salt thereof, where Ar1, Ar2, and Ar3 are independently selected from substituted or unsubstituted catechol groups and substituted or unsubstituted hydroxypyridinone (HOPO) groups.
